Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy

Leukemia volume 23, pages 983–985 (2009)Cite this article

The selective bcr-abl tyrosine kinase inhibitor imatinib has become the therapy of choice for patients with newly diagnosed chronic myelogenous leukaemia (CML) including those previously considered candidates for allogeneic haematopoietic stem cell transplantation. Major pathways downstream of bcr-abl are Grb2-Ras and p42/44 mitogen-activiated proteinkinase, phosphatidylinositol 3-kinase, nuclear factor-κB and the signal transducers and activators 1/5.1 Still, how bcr-abl downstream molecules are affected by bcr-abl inhibition through imatinib is not fully understood.

To identify ‘early response genes’ during imatinib therapy, we looked for changes in the transcriptome of Philadelphia chromosome-positive (Ph+) CD34+ cells from patients with de novo CML following 7 days of treatment.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Kawauchi K, Ogasawara T, Yasuyama M, Ohkawa S-I . Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells. Blood Cells Mol Dis 2003; 31: 11–17.

    Article  CAS  Google Scholar 

  2. Singhal S, Amin K, Kruklitis R, DeLong P, Friscia M, Litzky L et al. Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling. Cancer Biol Ther 2003; 2: 291–298.

    Article  CAS  Google Scholar 

  3. Bauerschmidt C, Pollok S, Kremmer E, Nasheuer H-P, Grosse F . Interactions of human Cdc45 with the Mcm2–7 complex, the GINS complex, and DNA polymerases delta and epsilon and during S phase. Genes Cells 2007; 12: 745–758.

    CAS  PubMed  Google Scholar 

  4. Gotter AL, Suppa C, Emanuel BS . Mammalian TIMELESS and Tipin are evolutionarily conserved replication fork-associated factors. J Mol Biol 2007; 366: 36–52.

    Article  CAS  Google Scholar 

  5. Venclovas C, Colvin ME, Thelen MP . Molecular modeling-based analysis of interactions in the RFC-dependent clamp-loading process. Protein Sci 2002; 11: 2403–2416.

    Article  CAS  Google Scholar 

  6. Gotte M, Yip GW . Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 2006; 66: 10233–10237.

    Article  Google Scholar 

  7. Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Rosskopf M et al. Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 2007; 21: 494–504.

    Article  CAS  Google Scholar 

  8. Morel JCM, Park CC, Woods JM, Koch AE . A novel role for interleukin-18 in adhesion molecule induction through NFkappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem 2001; 276: 37069–37075.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

DB is supported by a research grant of the ‘Forschungskommission’ of the Medical Faculty of the Heinrich-Heine-University Duesseldorf. The work is supported by a grant of the ‘Leukaemie Liga, Duesseldorf’ and by Novartis pharma. Thanks to Sabrina Pechtel and Gernot Roeder for preparing the Affymetrix gene arrays.

Author information

Authors and Affiliations

  1. Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany

    D Bruennert, A Czibere, I Bruns, R Kronenwett, N Gattermann, R Haas & F Neumann

Authors
  1. D Bruennert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Czibere
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I Bruns
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Kronenwett
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Gattermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F Neumann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Neumann.

Additional information

Contribution: DB: experiments and manuscript preparation; AC and IB: experiments and statistical analysis; RK: concept of study, manuscript preparation; NG and RH: manuscript preparation, concept of study; FN: experiments, manuscript preparation and concept of study.

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bruennert, D., Czibere, A., Bruns, I. et al. Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy. Leukemia 23, 983–985 (2009). https://doi.org/10.1038/leu.2008.337

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.337

This article is cited by

Search

Advanced search

Quick links